Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA OTCMKTS:BVNRY NASDAQ:KRYS NASDAQ:MESO NASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$9.23-0.4%$7.87$5.01▼$18.71$55.26M0.18117,699 shs35,334 shsBVNRYBavarian Nordic$9.12+1.4%$8.67$6.60▼$14.60$2.13B1.362,676 shs8,417 shsKRYSKrystal Biotech$148.90+3.9%$136.50$122.80▼$219.34$4.14B0.67286,959 shs538,250 shsMESOMesoblast$10.51+0.6%$11.24$5.78▼$22.00$1.34B2.39277,225 shs174,166 shsRCELAvita Medical$5.63+0.4%$6.27$4.71▼$14.16$148.30M1.52189,391 shs356,160 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-0.43%+11.88%-0.32%+74.15%+13.95%BVNRYBavarian Nordic+1.39%+3.28%-0.38%+27.20%+1.79%KRYSKrystal Biotech+3.88%+5.34%+9.42%-7.31%-23.09%MESOMesoblast+0.57%-3.22%-11.31%+1.06%+38.38%RCELAvita Medical+0.36%+8.90%-7.86%-34.76%-33.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics4.0946 of 5 stars3.33.00.04.70.62.50.6BVNRYBavarian NordicN/AN/AN/AN/AN/AN/AN/AN/AKRYSKrystal Biotech4.491 of 5 stars3.51.00.04.72.22.51.9MESOMesoblast1.9434 of 5 stars3.51.00.00.02.40.80.6RCELAvita Medical0.8502 of 5 stars3.40.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.57Moderate Buy$17.7592.31% UpsideBVNRYBavarian Nordic 0.00N/AN/AN/AKRYSKrystal Biotech 3.00Buy$211.1341.79% UpsideMESOMesoblast 3.00Buy$18.0071.27% UpsideRCELAvita Medical 2.75Moderate Buy$16.50193.07% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, RCEL, BVNRY, MESO, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral6/24/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.006/6/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.005/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.005/7/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$195.00 ➝ $189.005/7/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$219.00 ➝ $219.005/6/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.00 ➝ $240.004/28/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$221.00 ➝ $240.004/10/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$128.94M0.43N/AN/A($16.89) per share-0.55BVNRYBavarian Nordic$829.12M2.60$1.03 per share8.88$6.99 per share1.30KRYSKrystal Biotech$290.52M14.81$4.82 per share30.91$32.90 per share4.53MESOMesoblast$5.90M227.62N/AN/A$4.21 per share2.50RCELAvita Medical$71.66M2.08N/AN/A$0.17 per share33.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)BVNRYBavarian Nordic$143.26M$0.8011.408.69N/A21.11%11.89%9.32%8/28/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1635.7914.77N/A37.17%14.64%13.28%8/4/2025 (Estimated)MESOMesoblast-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)RCELAvita Medical-$61.85M-$2.19N/AN/AN/A-79.61%-632.62%-71.72%8/6/2025 (Estimated)Latest ATRA, RCEL, BVNRY, MESO, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025KRYSKrystal Biotech$1.20N/AN/AN/A$95.42 millionN/A5/15/2025Q1 2025ATRAAtara Biotherapeutics-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million5/9/2025Q1 2025BVNRYBavarian NordicN/A$0.13N/A$0.13N/A$189.89 million5/8/2025Q1 2025RCELAvita Medical-$0.39-$0.53-$0.14-$0.53$33.15 million$18.51 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ABVNRYBavarian NordicN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ARCELAvita MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.570.57BVNRYBavarian NordicN/A2.811.44KRYSKrystal BiotechN/A9.659.27MESOMesoblast0.220.960.63RCELAvita Medical9.392.091.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%BVNRYBavarian NordicN/AKRYSKrystal Biotech86.29%MESOMesoblast1.43%RCELAvita Medical27.66%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.00%BVNRYBavarian NordicN/AKRYSKrystal Biotech13.70%MESOMesoblast18.80%RCELAvita Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3305.96 million5.72 millionOptionableBVNRYBavarian Nordic1,611236.57 millionN/ANot OptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableMESOMesoblast80127.78 million103.76 millionOptionableRCELAvita Medical13026.44 million25.70 millionOptionableATRA, RCEL, BVNRY, MESO, and KRYS HeadlinesRecent News About These CompaniesAvita Medical Ltd (RCEL) Stock Forums - Investing.comJune 30, 2025 | investing.comAVITA Medical, Inc. (RCEL) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comAnalysts Expect Breakeven For AVITA Medical, Inc. (NASDAQ:RCEL) Before LongJune 21, 2025 | finance.yahoo.comCantor Fitzgerald Predicts AVITA Medical FY2026 EarningsJune 11, 2025 | marketbeat.comAVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™June 5, 2025 | finance.yahoo.comAVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough AwardsJune 3, 2025 | globenewswire.comAVITA Medical’s Acute Wound Care Showcase 2025 Streams Live TodayMay 13, 2025 | finance.yahoo.comAVITA Medical: Near-Perfect Execution Needed To Navigate Through Balance Sheet ChallengesMay 12, 2025 | seekingalpha.comAnalysts Have Been Trimming Their AVITA Medical, Inc. (NASDAQ:RCEL) Price Target After Its Latest ReportMay 11, 2025 | finance.yahoo.comAVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comAVITA Medical Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comAVITA Medical to Announce First Quarter 2025 Financial ResultsApril 17, 2025 | globenewswire.comAVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025April 9, 2025 | globenewswire.com6 Analysts Assess AVITA Medical: What You Need To KnowApril 6, 2025 | nasdaq.comAvita Medical announces U.S. commercial launch of CohealyxApril 4, 2025 | msn.comAVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market OpportunityApril 3, 2025 | globenewswire.comAVITA Medical’s SWOT analysis: regenerative medicine stock faces growth hurdlesMarch 21, 2025 | uk.investing.com4RCEL : What Analysts Are Saying About AVITA Medical StockMarch 18, 2025 | benzinga.comAvita Medical amends PermeaDerm distribution agreement with Stedical ScientificMarch 17, 2025 | markets.businessinsider.comAvita Medical Boosts Production with New AgreementMarch 17, 2025 | tipranks.comAVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical ScientificMarch 17, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseUPS Is Outpacing the Market: A Green Light for Investors?By Jeffrey Neal Johnson | June 27, 2025View UPS Is Outpacing the Market: A Green Light for Investors?ATRA, RCEL, BVNRY, MESO, and KRYS Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$9.23 -0.04 (-0.43%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$9.07 -0.16 (-1.68%) As of 07/9/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Bavarian Nordic OTCMKTS:BVNRY$9.12 +0.13 (+1.39%) As of 07/9/2025 11:46 AM EasternBavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.Krystal Biotech NASDAQ:KRYS$148.90 +5.56 (+3.88%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$148.92 +0.01 (+0.01%) As of 06:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Mesoblast NASDAQ:MESO$10.51 +0.06 (+0.57%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$10.58 +0.08 (+0.71%) As of 07/9/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Avita Medical NASDAQ:RCEL$5.63 +0.02 (+0.36%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$5.62 0.00 (-0.09%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
